🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daniel Diolaiti

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0002-3839-8814
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Papers

Driven by 6 papers — median percentile 80. Top paper: “Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers”.

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Cell(2020)10.1016/j.cell.2020.07.009
N/A
1.1DataRank · unranked
1205 citations

Han Sang Kim, Linda Bojmar, Kofi Ennu Gyan, Michele Cioffi, Jonathan M. Hernandez +95 more

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Preclinical evaluation of XPO1 inhibition in Wilms tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3580
N/A
0.104DataRank · unranked
1 citations

Armaan Siddiquee, Daoqi You, Prabhjot S. Mundi, Lianna J. Marks, Kristina Guillan +6 more

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.03.462951
N/A
0DataRank · unranked
7 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +48 more

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors – expanding patient-driven discovery beyond the N-of-1

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.02.462793
N/A
0DataRank · unranked
1 citations

Daniel Diolaiti, Prabhjot S. Mundi, Ervin S. Gaviria, Allison R. Rainey, Darrell J. Yamashiro +8 more

Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors

Med(2022)10.1016/j.medj.2022.09.002
N/A
0DataRank · unranked
20 citations

Prabhjot S. Mundi, Lianna J. Marks, Chelsey Burke, Michael V. Ortiz, Daniel Diolaiti +17 more